Abrdn Life Sciences Investors (HQL)
- Previous Close
12.95 - Open
13.01 - Bid 12.28 x 800
- Ask 13.36 x 1000
- Day's Range
12.96 - 13.03 - 52 Week Range
11.34 - 14.37 - Volume
165,031 - Avg. Volume
104,453 - Market Cap (intraday)
354.736M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
16.42 - EPS (TTM)
0.79 - Earnings Date Jun 3, 2024 - Jun 7, 2024
- Forward Dividend & Yield 1.33 (10.27%)
- Ex-Dividend Date Feb 21, 2024
- 1y Target Est
--
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
--
Full Time Employees
September 30
Fiscal Year Ends
Sector
Industry
Recent News: HQL
Performance Overview: HQL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HQL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HQL
Valuation Measures
Market Cap
354.19M
Enterprise Value
--
Trailing P/E
16.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.58
Price/Book (mrq)
0.88
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
156.45%
Return on Assets (ttm)
-0.32%
Return on Equity (ttm)
1.28%
Revenue (ttm)
3.51M
Net Income Avi to Common (ttm)
5.5M
Diluted EPS (ttm)
0.79
Balance Sheet and Cash Flow
Total Cash (mrq)
822
Total Debt/Equity (mrq)
2.21%
Levered Free Cash Flow (ttm)
--
Company Insights: HQL
HQL does not have Company Insights